Advectus Life Sciences Begins Preclinical Trials of P80DOX-NP
VANCOUVER, Canada-Ad-vectus Life Sciences Inc. has begun preclinical testing of its patented nanoparticle-based technology (Nanocure) at the University of North Carolina Brain Tumor Center. This series of studies will test the Nanocure
VANCOUVER, CanadaAd-vectus Life Sciences Inc. has begun preclinical testing of its patented nanoparticle-based technology (Nanocure) at the University of North Carolina Brain Tumor Center. This series of studies will test the Nanocure formulation P80DOX-NP on rodent brain metastases arising from lung, breast, renal cell, and colon cancers, and melanoma, the company announced.
P80DOX-NP is a novel method for the delivery of doxorubicin across the blood-brain barrier. The randomized, placebo-controlled study will measure survival as a surrogate for intracranial tumor progression/regression.
